Identification of epigenome-wide DNA methylation differences between carriers of APOE ε4 and APOE ε2
Mairead L. Bermingham,
Stewart W Morris,
David J Porteous,
Andrew M McIntosh,
Riccardo E Marioni,
Kathryn L. Evans
Posted 23 Oct 2019
bioRxiv DOI: 10.1101/815035
Posted 23 Oct 2019
BACKGROUND The Apolipoprotein E ( APOE ) ε4 allele is the strongest genetic risk factor for late onset Alzheimer’s disease, while the ε2 allele confers protection. Previous studies report differential DNA methylation of APOE between ε4 and ε2 carriers, but associations with epigenome-wide methylation have not previously been characterised. METHODS Using the EPIC array, we investigated epigenome-wide differences in whole blood DNA methylation patterns between Alzheimer’s disease-free APOE ε4 (n=2469) and ε2 (n=1118) carriers from the two largest single-cohort DNA methylation samples profiled to date. Using a discovery, replication and meta-analysis study design, methylation differences were identified using epigenome-wide association analysis and differentially methylated region (DMR) approaches. Results were explored using pathway and methylation quantitative trait loci (meQTL) analyses. RESULTS We obtained replicated evidence for DNA methylation differences in a ~169kb region, which encompasses part of APOE and several upstream genes. Meta-analytic approaches identified DNA methylation differences outside of APOE: differentially methylated positions were identified in DHCR24, LDLR and ABCG1 (2.59 x 10−100≤ P ≤2.44 x 10−8) and DMRs were identified in SREBF2 and LDLR (1.63 x 10−4≤ P ≤3.01 x 10−2). Pathway and meQTL analyses implicated lipid-related processes and high density lipoprotein cholesterol was identified as a partial mediator of the methylation differences in ABCG1 and DHCR24 . CONCLUSIONS APOE ε4 vs. ε2 carrier status is associated with epigenome-wide methylation differences in the blood. The loci identified are located in trans as well as cis to APOE and implicate genes involved in lipid homeostasis. ### Competing Interest Statement AMM has received grant support from Pfizer, Eli Lilly, Janssen and The Sackler Trust. These sources are not connected to the current investigation. AMM has also received speaker fees from Janssen and Illumina. The remaining authors report no conflicts of interest. * Aβ : amyloid beta AD : Alzheimer’s disease CI : confidence interval DMP : differentially methylated position DMR : differentially methylated region EWAS : epigenome-wide association study GS:SFHS : Generation Scotland: Scottish Family Health Study HDL : high density lipoprotein LDL : low density lipoprotein PC : principal component SNP : single nucleotide polymorphism
- Downloaded 299 times
- Download rankings, all-time:
- Site-wide: 71,658 out of 118,598
- In genetics: 3,448 out of 5,142
- Year to date:
- Site-wide: 51,392 out of 118,598
- Since beginning of last month:
- Site-wide: 51,934 out of 118,598
Downloads over time
Distribution of downloads per paper, site-wide
- 27 Nov 2020: The website and API now include results pulled from medRxiv as well as bioRxiv.
- 18 Dec 2019: We're pleased to announce PanLingua, a new tool that enables you to search for machine-translated bioRxiv preprints using more than 100 different languages.
- 21 May 2019: PLOS Biology has published a community page about Rxivist.org and its design.
- 10 May 2019: The paper analyzing the Rxivist dataset has been published at eLife.
- 1 Mar 2019: We now have summary statistics about bioRxiv downloads and submissions.
- 8 Feb 2019: Data from Altmetric is now available on the Rxivist details page for every preprint. Look for the "donut" under the download metrics.
- 30 Jan 2019: preLights has featured the Rxivist preprint and written about our findings.
- 22 Jan 2019: Nature just published an article about Rxivist and our data.
- 13 Jan 2019: The Rxivist preprint is live!